AFQ056
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fragile X Syndrome
Conditions
Fragile X Syndrome
Trial Timeline
Nov 1, 2011 → Sep 1, 2014
NCT ID
NCT01433354About AFQ056
AFQ056 is a phase 2/3 stage product being developed by Novartis for Fragile X Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT01433354. Target conditions include Fragile X Syndrome.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01491932 | Phase 2 | Completed |
| NCT01482143 | Phase 1 | Completed |
| NCT01433354 | Phase 2/3 | Terminated |
| NCT01348087 | Phase 2 | Terminated |
| NCT01456663 | Phase 1 | Completed |
| NCT01442259 | Phase 1 | Completed |
| NCT01173731 | Phase 2 | Completed |
| NCT00414856 | Phase 1 | Completed |
Competing Products
14 competing products in Fragile X Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CTH120 | Connecta Therapeutics | Phase 1 | 25 |
| AFQ056 | Novartis | Phase 1 | 33 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| AF056 + Placebo | Novartis | Phase 2 | 52 |
| Placebo + RO4917523 + RO4917523 | Roche | Phase 2 | 52 |
| Placebo (for RO4917523 ascending doses) + Placebo (for RO4917523 fixed dose) + RO4917523 + RO4917523 | Roche | Phase 2 | 52 |
| Placebo + RO4917523 0.5 mg + RO4917523 1.5 mg | Roche | Phase 2 | 52 |
| CBD Oral Solution + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| CBD Oral Solution (eCBD system Target) + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| Low dose of MRM-3379 + Middle Dose of MRM-3379 + High dose of MRM-3379 + Placebo + Low dose of MRM-3379 Open-Label | Mirum Pharmaceuticals | Phase 2 | 49 |
| NNZ-2566 + Placebo | Neuren Pharmaceuticals | Phase 2 | 47 |